ReviewFrontiers in immunology2026
Imbalanced IgA-IgG class switching recombination: a novel mechanism of gut immune dysregulation in inflammatory bowel disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disorder with significant disease burden that markedly impairs patients' quality of life. The pathogenesis of IBD is closely associated with hyperactive immunopathological responses. Emerging evidence has established humoral immunity as a crucial contributor to IBD development. Class switch recombination (CSR), the critical process enabling B cells to produce different antibody isotypes, plays a pivotal role in humoral immunity. While healthy intestinal mucosa predominantly contains immunoglobulin A (IgA) that maintains gut homeostasis, immunoglobulin G (IgG) becomes the dominant isotype during IBD and drives chronic inflammation. Therefore, understanding the signals and mechanisms governing antibody CSR may provide deeper insights into IBD pathogenesis. Herein, we review B cell activation pathways, the distinct roles of IgA and IgG in intestinal immunity, CSR-regulating signals, and recent discoveries in the context of IBD, with the aim of identifying novel therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.